New Delhi, Feb 20: ENTOD Pharmaceuticals today announced the launch of COLLADERM, a global breakthrough in regenerative skincare. Officially unveiled at the 54th National Conference of the Indian Association of Dermatologists, Venereologists & Leprologists (DERMACON 2026), COLLADERM introduces a first-in-class transdermal collagen gel serum designed for deep, structural skin regeneration. The product is now officially available in the market from February onwards.
Developed in the UK using advanced AI-driven bio-engineering and exclusively licensed to ENTOD Pharmaceuticals for the Indian market, the COLLADERM formulation has been further optimised at ENTOD’s DSIR-approved R&D center in India. The product has been refined to address Indian skin biology, climatic conditions, and real-world clinical requirements.
Collagen plays a central role in skin resilience, hydration, elasticity, and visible firmness. However, conventional collagen formats face practical limitations: injectable options are procedure-based and costly, oral collagen absorption can be inconsistent, and topical collagen often struggles to penetrate beyond the skin surface. COLLADERM is engineered to overcome these barriers through advanced collagen bio-engineering and transdermal delivery science, supporting visible skin renewal, enhanced hydration, improved firmness, and a rejuvenated appearance.
Speaking on the launch, Mr. Nikkhil K. Masurkar, CEO of ENTOD Pharmaceuticals, said
“COLLADERMreflects ENTOD’s commitment to translating world-class science into dermatologist-led skincare. While collagen is essential for youthful, resilient skin, many existing formats fail to deliver meaningful benefits beyond the surface. With COLLADERM, we have combined AI bio-engineered collagen with advanced transdermal delivery to enable deeper hydration, improved firmness, and visible skin rejuvenation, setting a new benchmark in regenerative skincare.”
At the core of COLLADERM is ENTOD’s proprietary Quattro Collagen System, which integrates Type III and Type XVII Recombinant Vegan Collagens (RVC), previously unavailable in India, in both high and low molecular weights for multi-depth biological action. This system is supported by TRANSCELLAR, a cold-processed transdermal liposomal delivery platform engineered to enhance penetration and cellular uptake. The formulation is further enriched with hyaluronic acid, glycerin, and vitamin C, supporting hydration, permeability, and collagen co-activation.
Commenting on the clinical relevance, Dr Jijith KR, Director & Chief Dermatologist, COSMALIFE Skin Clinic, Bangalore, said
“Collagen is fundamental to maintaining skin structure, elasticity, hydration, and a youthful appearance, yet many topical products fail to deliver meaningful outcomes due to poor penetration. Advanced collagen systems combined with enhanced delivery technologies can significantly improve clinical performance. COLLADERM represents a promising evolution in regenerative skincare, supporting improved hydration, smoother texture, and visibly refreshed skin. For patients seeking dermatologist-guided, science-driven skincare, this offers a sophisticated and modern collagen solution.”
Manufactured in India under the ‘Make in India’ initiative at an internationally accredited facility through an India–UK technology transfer collaboration, COLLADERM™️ reinforces ENTOD’s expanding footprint in dermatology-led innovation and advanced skincare science.
COLLADERM will be available exclusively through specialist dermatologist clinics and positioned as a prescription-led, science-first regenerative gel serum.
With over 48 years of scientific excellence, ENTOD continues to expand its research-driven portfolio across specialty healthcare, integrating deep medical research with next-generation formulation engineering.